DGX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Quest Diagnostics is a good buy right now for a beginner-focused, long-term investor with $50,000-$100,000 to invest. The stock is in a constructive uptrend, analyst sentiment has turned more positive after a strong Q1 beat and raised guidance, hedge funds are aggressively accumulating, and there are no negative event-driven headlines or insider selling pressure. The current price is near short-term resistance but the broader setup remains favorable, so I would buy now rather than wait for a perfect pullback.
DGX shows a bullish technical setup. MACD histogram is positive and expanding, indicating improving momentum. Moving averages are aligned bullishly with SMA_5 > SMA_20 > SMA_200, which supports an established uptrend. RSI_6 at 71.736 is elevated but still described as neutral in the data, suggesting momentum is strong without a clear reversal signal yet. Price at 203.8 is just below R1 at 205.125 and above the pivot at 198.828, so the stock is trading near breakout territory with nearby support at 192.531. The pattern-based forecast also suggests modest upside over the next day, week, and month.
["Multiple analysts raised price targets after Q1 results, with several maintaining Buy/Overweight ratings.", "Q1 earnings beat expectations and management raised FY26 guidance.", "Analysts highlighted strong organic volume growth as a key positive driver.", "Hedge funds are buying aggressively, with buying up 1536.08% over the last quarter.", "No news in the recent week removes near-term headline risk.", "Bullish technical structure supports continuation."]
["No recent news catalyst means the stock lacks an immediate fresh upside trigger.", "Price is close to first resistance at 205.125, so upside may be gradual from here.", "RSI is elevated, which can limit short-term follow-through strength.", "Insider activity is neutral, so there is no insider accumulation signal."]
The latest financial quarter appears to be Q1 2026. Financial data is not fully provided, but the analyst commentary indicates Quest delivered a solid beat on sales and EPS, with core and organic volume growth being the standout trend. Management also raised FY26 sales and EPS guidance, which points to improving operating momentum and better-than-expected growth trends.
Wall Street sentiment has improved meaningfully over the past few weeks. Truist, UBS, Baird, Barclays, Evercore ISI, Jefferies, and BofA all raised price targets following Q1 results. Ratings are mixed overall, ranging from Hold/Neutral to Buy/Overweight, but the direction of revisions is clearly positive. The pros view is that Quest is executing well, volumes are strong, and estimates may still have upside. The cons view is that several firms remain Neutral/In Line, implying upside may be steady rather than explosive.
